our Premium Content: News alerts, weekly reports and conference planners

GENE:

TOP2A (DNA topoisomerase 2-alpha)

News alerts, weekly reports and conference planners

Overexpression of Pin1 regulated by TOP2A, which subsequently stabilizes Pyk2 to promote bortezomib resistance in multiple myeloma. (PubMed, Cancer Gene Ther)

Moreover, Pin1 inhibition combined with Pyk2 inhibition decreases myeloma burden both in vitro and in vivo. Altogether, our findings reveal the tumor-promoting role of Pin1 in MM and provide evidence that targeting Pin1 could be a therapeutic strategy for MM.

6 days ago

Journal

TOP2A (DNA topoisomerase 2-alpha) • PIN1 (Peptidylprolyl Cis/Trans Isomerase, NIMA-Interacting 1)

bortezomib

Establishment of prognosis model of hepatocellular carcinoma based on prognosis related gene analysis and study on gene regulation mechanism of model. (PubMed, Heliyon)

In addition, the high expression of model gene produced drug resistance to trametinib, selumetinib and RDEA119 (refametinib). The prognostic risk model based on six prognostic related DEGs is an independent prognostic factor of HCC, which can effectively predict the survival and prognosis of HCC patients.

6 days ago

Journal

TOP2A (DNA topoisomerase 2-alpha) • CCNA2 (Cyclin A2) • CDC20 (Cell Division Cycle 20) • CDK1 (Cyclin-dependent kinase 1) • BUB1 (BUB1 Mitotic Checkpoint Serine/Threonine Kinase) • CCNB1 (Cyclin B1)

Mekinist (trametinib) • Koselugo (selumetinib) • refametinib (BAY86-9766)

Discovery of key molecular signatures for diagnosis and therapies of glioblastoma by combining supervised and unsupervised learning approaches. (PubMed, Sci Rep)

Finally, we recommended KGs-guided four repurposable drug molecules (Fluoxetine, Vatalanib, TGX221 and RO3306) against GBM through molecular docking, drug likeness, ADMET analyses and molecular dynamics simulation studies. Thus, the discoveries of this study could serve as valuable resources for wet-lab experiments in order to take a proper treatment plan against GBM.

6 days ago

Journal

TOP2A (DNA topoisomerase 2-alpha) • RAD51 (RAD51 Homolog A) • AURKA (Aurora kinase A) • CHEK1 (Checkpoint kinase 1) • RAD51AP1 (RAD51 Associated Protein 1) • CCNB2 (Cyclin B2) • CDK1 (Cyclin-dependent kinase 1) • MCM10 (Minichromosome Maintenance 10 Replication Initiation Factor) • CDCA8 (Cell Division Cycle Associated 8)

TGX-221 • fluoxetine • vatalanib (PTK787)

21d

Excessive MYC-topoisome activity triggers acute DNA damage, MYC degradation, and replacement by a p53-topoisome. (PubMed, Mol Cell)

Because p53, unlike MYC, upregulates the DNA-damage response (DDR) and activates tyrosyl-DNA-phosphodiesterase (TDP) 1 and TDP2, it suppresses further topoisome-mediated damage. The physical coupling and activation of TOP1 and TOP2 by p53 creates a tool that supports p53-target expression while braking MYC-driven proliferation in mammalian cells.

21 days ago

Journal

TP53 (Tumor protein P53) • TOP2A (DNA topoisomerase 2-alpha)

MYC expression

23d

Identifying the prognostic significance of mitophagy-associated genes in multiple myeloma: a novel risk model construction. (PubMed, Clin Exp Med)

The analysis of chemotherapy drug sensitivity revealed that etoposide and doxorubicin, which target TOP2A, exhibited superior treatment outcomes in the high-risk group. A novel prognostic model for MM was developed and validated, demonstrating significant potential in predicting patient outcomes and providing valuable guidance for personalized immunotherapy counseling.

23 days ago

Journal • IO biomarker

PD-L1 (Programmed death ligand 1) • TOP2A (DNA topoisomerase 2-alpha) • LAG3 (Lymphocyte Activating 3) • PD-L2 (Programmed Cell Death 1 Ligand 2) • CDC6 (Cell Division Cycle 6)

doxorubicin hydrochloride • etoposide IV

23d

Unveiling novel prognostic biomarkers and therapeutic targets for HBV-associated hepatocellular carcinoma through integrated bioinformatic analysis. (PubMed, Medicine (Baltimore))

Our research shows that ZWINT, MELK, DLGAP5, BIRC5, AURKA, HMMR, CDK1, TTK, and MAD2L1 may be useful for predicting how HBV-associated HCC will progress and for finding new ways to treat it. In addition to these further studies are needed to elucidate the functions of the remaining 11 identified hub genes (RRM2, NUSAP1, PBK, CCNB1, CCNB2, BUB1B, NEK2, CENPF, ASPM, TOP2A, and BUB1) in HCC development and progression.

23 days ago

Journal

TOP2A (DNA topoisomerase 2-alpha) • BIRC5 (Baculoviral IAP repeat containing 5) • AURKA (Aurora kinase A) • NUSAP1 (Nucleolar and Spindle Associated Protein 1) • MELK (Maternal Embryonic Leucine Zipper Kinase) • RRM2 (Ribonucleotide Reductase Regulatory Subunit M2) • CCNB2 (Cyclin B2) • CDK1 (Cyclin-dependent kinase 1) • BUB1 (BUB1 Mitotic Checkpoint Serine/Threonine Kinase) • BUB1B (BUB1 Mitotic Checkpoint Serine/Threonine Kinase B) • CCNB1 (Cyclin B1) • MAD2L1 (Mitotic Arrest Deficient 2 Like 1) • ZWINT (ZW10 Interacting Kinetochore Protein)

24d

Targeting the 3D genome by anthracyclines for chemotherapeutic effects. (PubMed, bioRxiv)

Furthermore, AML patients receiving anthracycline drugs showed altered chromatin structures around potential looping anchors, which linked to distinct clinical outcomes. Our data indicate that anthracyclines are potent and selective epigenomic targeting drugs and can target the 3D genome for anticancer therapy, which could be used for personalized medicine to treat tumors with aberrant 3D chromatin structures.

24 days ago

Journal

TOP2A (DNA topoisomerase 2-alpha)

26d

Molecular Landscape of Bladder Cancer: Key Genes, Transcription Factors, and Drug Interactions. (PubMed, Int J Mol Sci)

This study provides valuable insights into key genes and their roles in bladder cancer. The identified genes and their interactions with therapeutic drugs could serve as potential biomarkers, presenting new opportunities for enhancing the diagnosis and prognosis of bladder cancer.

26 days ago

Journal

TOP2A (DNA topoisomerase 2-alpha) • IL6 (Interleukin 6) • AURKA (Aurora kinase A) • PLK1 (Polo Like Kinase 1) • AURKB (Aurora Kinase B) • CCNA2 (Cyclin A2) • FOXM1 (Forkhead Box M1) • CDK1 (Cyclin-dependent kinase 1) • CCNB1 (Cyclin B1)

26d

Elucidating the prognostic and therapeutic significance of TOP2A in various malignancies. (PubMed, Cancer Genet)

The increased expression of TOP2A is associated with poor clinical outcomes, indicating its potential as a valuable biomarker for assessing risk and stratifying treatment in these malignancies. However, further investigation is needed to elucidate the underlying mechanisms by which TOP2A influences cancer progression and to explore its potential as a therapeutic target.

26 days ago

Review • Journal

TOP2A (DNA topoisomerase 2-alpha)

TOP2A amplification • TOP2A expression

26d

Gene-expression profile analysis to disclose diagnostics and therapeutics biomarkers for thyroid carcinoma. (PubMed, Comput Biol Chem)

Then we detected 6 repurposable drug molecules (Entrectinib, Imatinib, Ponatinib, Sorafenib, Retevmo, and Pazopanib) by molecular docking with KGs-mediated receptor proteins, ADME/T analysis, and cross-validation with the independent receptors. Therefore, these findings might be useful resources for wet lab researchers and clinicians to consider an effective treatment strategy against THCA.

26 days ago

Journal • Gene Expression Profile

TOP2A (DNA topoisomerase 2-alpha) • TIMP1 (Tissue inhibitor of metalloproteinases 1) • RUNX2 (RUNX Family Transcription Factor 2)

KIM1 expression • TIMP1 expression

sorafenib • Rozlytrek (entrectinib) • imatinib • Iclusig (ponatinib) • pazopanib • Retevmo (selpercatinib)

28d

Exploring the anticancer potential of Lasia spinosa rhizomes: insights from molecular docking and DFT investigations on chlorogenic acid and beyond. (PubMed, Nat Prod Res)

Additionally, density functional theory studies indicated the strong electrophilic nature of CA and its potential for robust enzyme binding interactions. Subsequent MTT assays focusing on CA exhibited significant activity against all tested cell lines, with IC50 values ranging from 21.56 to 72.60 μg/ml, comparable to quercetin.

28 days ago

Journal

KDR (Kinase insert domain receptor) • TOP2A (DNA topoisomerase 2-alpha) • CDK2 (Cyclin-dependent kinase 2)

chlorogenic acid

29d

Adjuvant Docetaxel and Cyclophosphamide With or Without Epirubicin for Early Breast Cancer: Final Analysis of the Randomized DBCG 07-READ Trial. (PubMed, J Clin Oncol)

In conclusion, anthracycline followed by docetaxel improved outcome compared with DC in patients with TOP2A normal early breast cancer, and no clinical value of TOP2A testing was shown. The risk of HF was doubled in patients receiving anthracycline; however, overall, the risk of HF was low.

29 days ago

Journal

TOP2A (DNA topoisomerase 2-alpha)

docetaxel • cyclophosphamide • epirubicin

2ms

Integrated bioinformatics reveals genetic links between visceral obesity and uterine tumors. (PubMed, Mol Genet Genomics)

These findings deepen our understanding of disease etiology and offer promising avenues for drug repurposing. Experimental validation is needed to translate these insights into clinical applications and innovative treatments.

2 months ago

Journal

TOP2A (DNA topoisomerase 2-alpha) • TYMS (Thymidylate Synthetase) • APOE (Apolipoprotein E)

2ms

Low level exposure to BDE-47 facilitates the development of prostate cancer through TOP2A/LDHA/lactylation positive feedback circuit. (PubMed, Environ Res)

Furthermore, lactate upregulated TOP2A transcription through lactylation of H3K18la in PCa cells, which could be rescued by LDHA knockdown. Taken together, low dose BDE-47 triggered PCa progression through TOP2A/LDHA/lactylation positive feedback circuit, thus revealing epigenetic shifting and metabolic reprogramming underpinning BDE-47-induced carcinogenesis of the prostate.

2 months ago

Journal

LDHA (Lactate dehydrogenase A) • TOP2A (DNA topoisomerase 2-alpha) • PIK3R1 (Phosphoinositide-3-Kinase Regulatory Subunit 1) • FGF2 (Fibroblast Growth Factor 2) • CAV2 (Caveolin 2)

TOP2A expression

2ms

Mechanisms of Berberine in anti-pancreatic ductal adenocarcinoma revealed by integrated multi-omics profiling. (PubMed, Sci Rep)

BBR potentially targets CDK1, CCNB1, CTNNB1, CDK2, TOP2A, MCM2, RUNX2, MYC, PLK1, and AURKA to exert therapeutic effects on PDAC. The mechanisms of action appear to significantly involve macrophage polarization-related immunological responses.

2 months ago

Journal

CD8 (cluster of differentiation 8) • TOP2A (DNA topoisomerase 2-alpha) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • AURKA (Aurora kinase A) • PLK1 (Polo Like Kinase 1) • CDK2 (Cyclin-dependent kinase 2) • CDK1 (Cyclin-dependent kinase 1) • CCNB1 (Cyclin B1) • MCM2 (Minichromosome maintenance complex component 2) • RUNX2 (RUNX Family Transcription Factor 2)

2ms

Identification of potential core genes in lung cancer and therapeutic traditional Chinese medicine compounds using bioinformatics analysis. (PubMed, Medicine (Baltimore))

CDC20, CCNB2, and TOP2A are novel hub genes associated with LC. Paclitaxel, quercetin, and rotenone can be used as therapeutic agents in TCM.

2 months ago

Journal

TOP2A (DNA topoisomerase 2-alpha) • CCNB2 (Cyclin B2) • CDC20 (Cell Division Cycle 20)

CDC20 overexpression

paclitaxel

2ms

Overexpression of CDC25A, AURKB, and TOP2A Genes Could Be an Important Clue for Luminal A Breast Cancer. (PubMed, Eur J Breast Health)

The genes CDC25A, AURKB, and TOP2A may play crucial functions in LUM A pathogenesis. Therapeutic strategies that diminish the expression of these connected genes may enhance the prognosis of LUM A patients.

2 months ago

Journal

TOP2A (DNA topoisomerase 2-alpha) • AURKB (Aurora Kinase B) • CDC25A (Cell Division Cycle 25A) • GNRP (Ras-Specific Guanine Nucleotide-Releasing Factor 1)

2ms

Castration-resistant prostate cancer monitoring by cell-free circulating biomarkers. (PubMed, Front Oncol)

miR-375 is currently the most promising candidate among non-coding RNAs and sphingolipid analysis has recently emerged as a novel approach. The promising biomarkers have the potential to improve the care of metastatic prostate cancer patients, however, they need further validation for routine implementation.

2 months ago

Review • Journal

AR (Androgen receptor) • TOP2A (DNA topoisomerase 2-alpha) • MIR375 (MicroRNA 375) • CRP (C-reactive protein)

2ms

Identification of ubiquitin markers for survival and prognosis of ovarian cancer. (PubMed, Heliyon)

Therefore, suggesting the involvement of ubiquitin genes in the survival and development of OC through neurohumoral regulation. Our results will provide valuable reference or supplementary information for studies investigating OC diagnosis and therapies.

2 months ago

Journal • BRCA Biomarker

BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • TOP2A (DNA topoisomerase 2-alpha) • FANCA (FA Complementation Group A) • BARD1 (BRCA1 Associated RING Domain 1)

2ms

Super-silencer perturbation by EZH2 and REST inhibition leads to large loss of chromatin interactions and reduction in cancer growth. (PubMed, Nat Struct Mol Biol)

To perturb the super-silencers, we applied combinational treatment of an enhancer of zeste homolog 2 inhibitor GSK343, and a repressor element 1-silencing transcription factor inhibitor, X5050 ('GR')...Moreover, GR synergistically upregulated super-silencer-controlled genes related to cell cycle, apoptosis and DNA damage, leading to anticancer effects in vivo. Overall, our data demonstrated a super-silencer example and showed that GR can disrupt super-silencers, potentially leading to cancer ablation.

2 months ago

Journal

TOP2A (DNA topoisomerase 2-alpha) • FGF18 (Fibroblast Growth Factor 18)

GSK343

2ms

Ailanthone suppresses cell proliferation of renal cell carcinoma partially via inhibition of EZH2. (PubMed, Discov Oncol)

Altogether, we identified the anticancer role of Ail in RCC, including inhibition of cell proliferation and induction of apoptosis. The results also screened the key proteins mediate the function of Ail, which have laid a theoretical foundation for elucidating the applications of Ail in clinical research.

2 months ago

Journal

EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit) • TOP2A (DNA topoisomerase 2-alpha) • CDC20 (Cell Division Cycle 20) • CEP55 (Centrosomal Protein 55) • UBE2C (Ubiquitin Conjugating Enzyme E2 C)

2ms

Marine Compound-Carpatamide D as a Potential Inhibitor Against TOP2A and Its Mutant D1021Y in Colorectal Cancer: Insights from DFT, MEP and Molecular Dynamics Simulation. (PubMed, Mol Biotechnol)

Molecular mechanics/Poisson-Boltzmann surface area calculations indicated that TOP2A_28641 and D1021Y_28641 complexes exhibited the lowest binding energy of - 23.55 kcal/mol and - 25.03 kcal/mol, respectively. Our findings suggest carpatamide D as a promising lead compound for the TOP2A_D1021Y targeted cancer therapies, which needs further experimental validation.

2 months ago

Journal

TOP2A (DNA topoisomerase 2-alpha)

2ms

Identification of circadian clock-related immunological prognostic index and molecular subtypes in prostate cancer. (PubMed, Discov Oncol)

In this study, we established CIC-related immunological prognostic index and molecular subtypes, which might be useful for the clinical practice.

2 months ago

Journal

TOP2A (DNA topoisomerase 2-alpha) • ALDH2 (Aldehyde Dehydrogenase 2 Family Member) • APOE (Apolipoprotein E)

2ms

Expression and biological significance of topoisomerase II α (TOP2A) in oral squamous cell carcinoma. (PubMed, Discov Oncol)

The up-regulation of TOP2A may play a pivotal role in OSCC.

2 months ago

Journal

TOP2A (DNA topoisomerase 2-alpha)

TOP2A expression

3ms

Identification of Hub of the Hub-Genes From Different Individual Studies for Early Diagnosis, Prognosis, and Therapies of Breast Cancer. (PubMed, Bioinform Biol Insights)

Finally, we suggested hHubGs-guided top-ranked 10 candidate drug molecules (SORAFENIB, AMG-900, CHEMBL1765740, ENTRECTINIB, MK-6592, YM201636, masitinib, GSK2126458, TG-02, and PAZOPANIB) by molecular docking analysis for the treatment against BC. The literature review also supported our findings much more for BC compared with the results of individual studies. Therefore, the findings of this study may be useful resources for early diagnosis, prognosis, and therapies of BC.

3 months ago

Journal

EGFR (Epidermal growth factor receptor) • ER (Estrogen receptor) • TP53 (Tumor protein P53) • CCND1 (Cyclin D1) • TOP2A (DNA topoisomerase 2-alpha) • CCNA2 (Cyclin A2) • CDK1 (Cyclin-dependent kinase 1) • CCNB1 (Cyclin B1)

sorafenib • Rozlytrek (entrectinib) • pazopanib • omipalisib (GSK2126458) • AMG 900 • zotiraciclib (TG02) • Kinaction (masitinib)

3ms

Esophageal chemical burns as a risk factor for esophageal malignancies: in-silico analyses - experimental research. (PubMed, Ann Med Surg (Lond))

In sum, esophageal chemical burns can be related to the occurrence of esophageal cancer. Moreover, esophageal chemical burn is an external factor that upregulates present genes and can be regarded as a worsening prognosis or risk factor for esophageal cancer.

3 months ago

Journal

TOP2A (DNA topoisomerase 2-alpha) • BIRC5 (Baculoviral IAP repeat containing 5) • CCNA2 (Cyclin A2) • NUSAP1 (Nucleolar and Spindle Associated Protein 1) • MELK (Maternal Embryonic Leucine Zipper Kinase) • RRM2 (Ribonucleotide Reductase Regulatory Subunit M2) • CCNB2 (Cyclin B2) • CDC20 (Cell Division Cycle 20) • CDK1 (Cyclin-dependent kinase 1) • KIF11 (Kinesin Family Member 11) • BUB1 (BUB1 Mitotic Checkpoint Serine/Threonine Kinase) • BUB1B (BUB1 Mitotic Checkpoint Serine/Threonine Kinase B) • CCNB1 (Cyclin B1) • CEP55 (Centrosomal Protein 55) • KIF20A (Kinesin Family Member 20A) • KIF4A (Kinesin Family Member 4A) • PCLAF (PCNA Clamp Associated Factor)

3ms

Integrating network analysis with differential expression to uncover therapeutic and prognostic biomarkers in esophageal squamous cell carcinoma. (PubMed, Front Mol Biosci)

We also identify the molecules targeting these essential hub genes, among which GSK461364 is a promising inhibitor of PLK1, BMS265246, and Valrubicin inhibitors of CDK1 and TOP2A, respectively. Notably, MMP9 emerged as a significant prognostic marker with high expression correlating with poor survival, underscoring its potential for targeted therapy. These findings enhance our understanding of ESCC pathogenesis and highlight promising avenues for treatment.

3 months ago

Journal

TOP2A (DNA topoisomerase 2-alpha) • PLK1 (Polo Like Kinase 1) • MMP9 (Matrix metallopeptidase 9) • CDK1 (Cyclin-dependent kinase 1) • MAD2L1 (Mitotic Arrest Deficient 2 Like 1)

MMP9 elevation • TOP2A expression

GSK461364 • valrubicin

3ms

Identification of a novel RAB6A::TOP2A fusion in acute non-promyelocytic leukemia harboring t(11;17)(q13;q21) translocation. (PubMed, Virchows Arch)

No abstract available

3 months ago

Journal

TOP2A (DNA topoisomerase 2-alpha)

3ms

Single-cell transcriptomics reveals tumor landscape in ovarian carcinosarcoma. (PubMed, J Zhejiang Univ Sci B)

This study provides the single-cell transcriptomics signature of human OCS, which constitutes a new resource for elucidating OCS diversity.

3 months ago

Journal • BRCA Biomarker

BRCA1 (Breast cancer 1, early onset) • TOP2A (DNA topoisomerase 2-alpha) • IGF2 (Insulin-like growth factor 2) • WIF1 (WNT Inhibitory Factor 1)

3ms

In silico and in vitro analyses to investigate the effects of vitamin C on VEGF protein. (PubMed, J Taibah Univ Med Sci)

Increased apoptosis after treatment with vitamin C was observed due to upregulation of p53 and annexin V. The results of this study showed that vitamin C inhibited the growth of cancer cells, thus protecting HepG2 cells from oxidative stress. Vitamin C exhibited antiproliferative activity as observed in silico and in vitro, as well as by the inhibited expression of genes involved in protein synthesis.

3 months ago

Preclinical • Journal

VEGFA (Vascular endothelial growth factor A) • TOP2A (DNA topoisomerase 2-alpha) • PCNA (Proliferating cell nuclear antigen) • ANXA5 (Annexin A5)

3ms

Eleven inflammation-related genes risk signature model predicts prognosis of patients with breast cancer. (PubMed, Transl Cancer Res)

We identified 67 approved drugs that showed a different effect between the high- and low-risk patients and the top 2 gene-drug pairs were IL12B-sunitinib and SCARF1-ruxolitinib. The 11-IRG risk signature model is a promising tool to predict the survival of breast cancer patients and the expressions of IL12B and SCARF1 may serve as potential targets for therapy of breast cancer.

3 months ago

Journal • Tumor mutational burden

TMB (Tumor Mutational Burden) • TOP2A (DNA topoisomerase 2-alpha) • CCL2 (Chemokine (C-C motif) ligand 2) • IL18 (Interleukin 18) • RASGRP1 (RAS Guanyl Releasing Protein 1) • ABCA1 (ATP Binding Cassette Subfamily A Member 1) • CALCRL (Calcitonin Receptor Like Receptor) • CLEC5A (C-Type Lectin Domain Containing 5A)

sunitinib • Jakafi (ruxolitinib)

3ms

Biomarkers in Tumor Tissue Samples From Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer (clinicaltrials.gov)

P=N/A, N=169, Completed, Gynecologic Oncology Group | Not yet recruiting --> Completed

3 months ago

Trial completion • Metastases

HER-2 (Human epidermal growth factor receptor 2) • TOP2A (DNA topoisomerase 2-alpha)

3ms

Single-cell RNA sequencing reveals that MYBL2 in malignant epithelial cells is involved in the development and progression of ovarian cancer. (PubMed, Front Immunol)

Furthermore, immune infiltration and drug sensitivity analyses demonstrated increased responsiveness to Paclitaxel, Cisplatin, and Gemcitabine in the Low TTRS Group. We have revealed the heightened susceptibility of the C2 TOP2A+ TCs subgroup to neoadjuvant chemotherapy and emphasized the role of MYBL2 within the C2 subgroup in promoting the occurrence and progression of ovarian cancer. These insights provide valuable guidance for the management of ovarian cancer treatment.

3 months ago

Journal • IO biomarker

TOP2A (DNA topoisomerase 2-alpha) • MYBL2 (MYB Proto-Oncogene Like 2)

cisplatin • gemcitabine • paclitaxel

4ms

Single-cell tumor heterogeneity landscape of hepatocellular carcinoma: unraveling the pro-metastatic subtype and its interaction loop with fibroblasts. (PubMed, Mol Cancer)

By establishing a heterogeneity landscape of malignant cells, we identified a three-subtype classification in HCC. Among them, S100A6+ tumor cells play a crucial role in metastasis. Targeting the feedback loop between tumor cells and fibroblasts is a promising anti-metastatic strategy.

4 months ago

Journal • Metastases

TOP2A (DNA topoisomerase 2-alpha) • SPP1 (Secreted Phosphoprotein 1) • TGFB1 (Transforming Growth Factor Beta 1) • CTGF (Connective tissue growth factor) • S100A6 (S100 calcium binding protein A6) • SMAD3 (SMAD Family Member 3) • TGFBR1 (Transforming Growth Factor Beta Receptor 1)

4ms

Identification of key genes associated with cervical cancer based on bioinformatics analysis. (PubMed, BMC Cancer)

This study showed that TOP2A, AURKA, CCNA2 and IGFBP5 screened through bioinformatics analysis were significantly differentially expressed in cervical cancer samples compared with normal samples, which might be biomarkers of cervical cancer.

4 months ago

Journal

TOP2A (DNA topoisomerase 2-alpha) • AURKA (Aurora kinase A) • CCNA2 (Cyclin A2) • IGFBP5 (Insulin Like Growth Factor Binding Protein 5)

4ms

The liquid-liquid phase separation signature predicts the prognosis and immunotherapy response in hepatocellular carcinoma. (PubMed, J Cell Mol Med)

In vitro experiments verified that knockdown of MAPT could inhibit the proliferation and migration of HCC. The LLPSI identified in this study can accurately assess the prognosis of patients with HCC and identify patient populations that will benefit from immunotherapy, providing valuable insights into the clinical management of HCC.

4 months ago

Journal

TOP2A (DNA topoisomerase 2-alpha) • PLK1 (Polo Like Kinase 1) • MAPT (Microtubule Associated Protein Tau) • CDCA8 (Cell Division Cycle Associated 8) • WDR62 (WD Repeat Domain 62)

4ms

CX-5461 Preferentially Induces Top2α-Dependent DNA Breaks at Ribosomal DNA Loci. (PubMed, Biomedicines)

Most strikingly, and in contrast to canonical Top2α poisons, we found that the Top2α-dependent DNA damage induced by CX-5461 is preferentially localized at the ribosomal DNA (rDNA) promoter region, thereby highlighting CX-5461 as a loci-specific DNA damaging agent. This mechanism underpins the efficacy of CX-5461 against certain types of cancer and can be used to develop effective non-genotoxic anticancer drugs.

4 months ago

Journal

TOP2A (DNA topoisomerase 2-alpha)

pidnarulex (CX-5461)

4ms

Integrative genomic analysis reveals cancer-associated mutations in patients with ophthalmic tumors. (PubMed, J Int Med Res)

TP53 is clearly involved in ophthalmic tumorigenesis, especially in basal cell carcinoma, and the PI3K-Akt signaling pathway may be an essential pathway involved in ophthalmic tumorigenesis. RUNX1, SMO, TOP2A, and ZWINT are also highly likely to be involved in ophthalmic tumorigenesis, but further functional experiments are needed to verify the mechanisms of these genes in regulating tumorigenesis.

4 months ago

Retrospective data • Journal • BRCA Biomarker

TP53 (Tumor protein P53) • BRCA2 (Breast cancer 2, early onset) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • RUNX1 (RUNX Family Transcription Factor 1) • BAP1 (BRCA1 Associated Protein 1) • TOP2A (DNA topoisomerase 2-alpha) • PTCH1 (Patched 1) • MUC16 (Mucin 16, Cell Surface Associated) • TTN (Titin) • HBA1 (Hemoglobin Subunit Alpha 1) • HBB (Hemoglobin Subunit Beta) • ZWINT (ZW10 Interacting Kinetochore Protein)

4ms

Combined inhibition of EZH2 and CDK4/6 perturbs endoplasmic reticulum-mitochondrial homeostasis and increases antitumor activity against glioblastoma. (PubMed, NPJ Precis Oncol)

He, we show that combined use of the EZH2 inhibitor GSK126 and the CDK4/6 inhibitor abemaciclib synergistically enhances antitumoral effects in preclinical GBM models. Mechanistically, this was due to transcriptional changes in genes involved in mitotic aberrations/spindle assembly (Rb, PLK1, RRM2, PRC1, CENPF, TPX2), histone modification (HIST1H1B, HIST1H3G), DNA damage/replication stress events (TOP2A, ATF4), immuno-oncology (DEPDC1), EMT-counterregulation (PCDH1) and a shift in the stemness profile towards a more differentiated state. We propose a dual EZH2/CDK4/6 blockade for further investigation.

4 months ago

Journal

TOP2A (DNA topoisomerase 2-alpha) • CDK4 (Cyclin-dependent kinase 4) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • PLK1 (Polo Like Kinase 1) • CALR (Calreticulin) • RRM2 (Ribonucleotide Reductase Regulatory Subunit M2) • ATF4 (Activating Transcription Factor 4)

Verzenio (abemaciclib) • GSK2816126

4ms

Application of Transcriptome-Based Gene Set Featurization for Machine Learning Model to Predict the Origin of Metastatic Cancer. (PubMed, Curr Issues Mol Biol)

The external validation results demonstrate a top-1 accuracy ranging from 0.80 to 0.86, with a top-2 accuracy of 0.90. This study highlights that incorporating biological knowledge through curated gene sets can help to merge gene expression data from different platforms, thereby enhancing the compatibility needed to develop more effective machine learning prediction models.

4 months ago

Journal • Machine learning • Metastases

TOP2A (DNA topoisomerase 2-alpha)

4ms

Identification of Hub Genes for Psoriasis and Cancer by Bioinformatic Analysis. (PubMed, Biomed Res Int)

This study revealed some genetic mechanisms of psoriasis and cancer by bioinformatic analysis. These hub genes, hub TFs, and predicted drugs may provide new perspectives for further research on the mechanism and treatment.

4 months ago

Journal • BRCA Biomarker

BRCA1 (Breast cancer 1, early onset) • TOP2A (DNA topoisomerase 2-alpha) • AURKA (Aurora kinase A) • CD4 (CD4 Molecule) • AURKB (Aurora Kinase B) • CCNB2 (Cyclin B2) • NCAPG (Non-SMC Condensin I Complex Subunit G) • BUB1 (BUB1 Mitotic Checkpoint Serine/Threonine Kinase) • BUB1B (BUB1 Mitotic Checkpoint Serine/Threonine Kinase B) • CCNB1 (Cyclin B1) • E2F1 (E2F transcription factor 1) • E2F3 (E2F transcription factor 3) • KIF20A (Kinesin Family Member 20A)

4ms

Identification of novel biomarkers and potential molecular targets for uterine cancer using network-based approach. (PubMed, Pathol Res Pract)

Our study suggests that among these genes, KIF11 and H PGDS appeared to be novel key genes identified in our research. We also identified these key genes interactions with miRNAs.

4 months ago

Journal

CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • TOP2A (DNA topoisomerase 2-alpha) • RAD51 (RAD51 Homolog A) • AURKA (Aurora kinase A) • PLK1 (Polo Like Kinase 1) • FGF2 (Fibroblast Growth Factor 2) • AURKB (Aurora Kinase B) • CCNA2 (Cyclin A2) • CDC20 (Cell Division Cycle 20) • CDK1 (Cyclin-dependent kinase 1) • KIF11 (Kinesin Family Member 11) • PRKCA (Protein Kinase C Alpha) • BUB1 (BUB1 Mitotic Checkpoint Serine/Threonine Kinase) • BUB1B (BUB1 Mitotic Checkpoint Serine/Threonine Kinase B) • CAMK2A (Calcium/Calmodulin Dependent Protein Kinase II Alpha) • CCNB1 (Cyclin B1) • CDCA8 (Cell Division Cycle Associated 8) • KIF20A (Kinesin Family Member 20A) • KIF23 (Kinesin Family Member 23) • KIF2C (Kinesin Family Member 2C)